Cumberland Pharmaceuticals Inc Dossier - Source-backed chat

Cumberland Pharmaceuticals Inc

CPIXNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.40

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $7.51Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $112.5M

Enterprise Value $113.9M

Shares Outstanding 14.9M diluted

Moat Rating None

Next Earnings Date3 Nov 2026

Last ex-dividend3 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Cumberland Pharmaceuticals is undergoing a major strategic transformation. By selling its entire FDA-approved commercial product portfolio to Apotex for $100 million in cash, the company is unlocking significant immediate value relative to its micro-cap valuation. Post-transaction, Cumberland will transition into a pure-play biopharmaceutical development company, retaining its late-stage clinical pipeline (led by ifetroban) and its majority stake in Cumberland Emerging Technologies. This cash infusion provides a robust runway to fund its clinical programs without dilutive financing, presenting a highly asymmetric risk-reward profile.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$3.0010%

Shareholders reject the Apotex transaction or closing conditions are not met, forcing Cumberland to retain its commercial portfolio under continued margin pressure and high operating expenses, while clinical trials face funding constraints.

Base CaseCentral scenario

$6.5060%

The Apotex transaction is approved by shareholders on June 24, 2026, and closes successfully. The company utilizes the $100 million cash proceeds to eliminate its remaining debt and fully fund its Phase II clinical programs for ifetroban in systemic sclerosis, DMD, and idiopathic pulmonary fibrosis, while the market re-rates the stock closer to its cash-backed asset value.

Bull CaseUpside scenario

$8.5030%

The Apotex transaction closes smoothly, injecting $100 million in cash (exceeding the current market cap of ~$87 million). Post-close, Cumberland successfully advances ifetroban for DMD cardiomyopathy through FDA approval under Fast Track status, capturing a high-value orphan drug market.

Scenarios reflect our research view at the research date.

Key Investment Merits

Transformational $100 million cash transaction with Apotex unlocks value far exceeding the company's current market capitalization.
Transition to a well-funded, pure-play development model eliminates near-term dilution risk for clinical programs.
Ifetroban pipeline holds Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for DMD cardiomyopathy.

Key Investment Risks

Transaction completion risk dependent on shareholder approval at the June 24, 2026 special meeting.
Clinical development risk associated with late-stage Phase II programs failing to meet primary endpoints or regulatory approval requirements.
Loss of immediate commercial revenue streams post-transaction, making the company entirely dependent on pipeline milestones.

Thesis Invalidation Triggers

Failure to obtain shareholder approval for the Apotex asset sale.
Termination of the Asset Purchase Agreement with Apotex prior to closing.
Negative clinical trial results or FDA safety holds on the ifetroban development program.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.